Research programme: amyloid precursor protein secretase inhibitors - ESBATech
Latest Information Update: 06 Dec 2010
At a glance
- Originator ESBATech
- Class Small molecules
- Mechanism of Action Amyloid precursor protein secretase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 19 May 2005 This programme is available for licensing (http://www.esbatech.com)
- 26 Mar 2004 Preclinical trials in Alzheimer's disease in Switzerland (unspecified route)